APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Infections Assays

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hospital-Acquired Infections Assays Market Outlook and Growth Opportunities 2026

4 March 2026193 pages

Choose your research edition.

Industry ResearchHospital-Acquired Infections Assays Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Infections Assays Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Infections Assays Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Infections Assays Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Infections Assays Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Infections Assays market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hospital-Acquired Infections Assays is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hospital-Acquired Infections Assays is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hospital-Acquired Infections Assays is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hospital-Acquired Infections Assays market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hospital-Acquired Infections Assays market include BIOMÉRIEUX, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, BD (Becton, Dickinson and Company), Bioscience, Inc., QIAGEN, Thermo Fisher Scientific Inc. and Meridian Bioscience, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hospital-Acquired Infections Assays market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hospital-Acquired Infections Assays and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hospital-Acquired Infections Assays revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hospital-Acquired Infections Assays market.

Hospital-Acquired Infections Assays Segment by Company

BIOMÉRIEUX

Abbott

F. Hoffmann-La Roche Ltd.

Siemens Healthcare Private Limited

BD (Becton, Dickinson and Company)

Bioscience, Inc.

QIAGEN

Thermo Fisher Scientific Inc.

Meridian Bioscience, Inc.

Hologic, Inc.

Hospital-Acquired Infections Assays Segment by Type

Blood Tests

Urinalysis

Hospital-Acquired Infections Assays Segment by Application

Urinary Tract Infections

Pneumonia

Surgical Site Infections

Bloodstream Infections

Other Hospital Infections

Hospital-Acquired Infections Assays Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hospital-Acquired Infections Assays status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hospital-Acquired Infections Assays key companies, revenue, market share, and recent developments.

3. To split the Hospital-Acquired Infections Assays breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hospital-Acquired Infections Assays market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hospital-Acquired Infections Assays significant trends, drivers, influence factors in global and regions.

6. To analyze Hospital-Acquired Infections Assays competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Infections Assays market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Infections Assays and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Infections Assays.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hospital-Acquired Infections Assays industry.

Chapter 3: Detailed analysis of Hospital-Acquired Infections Assays company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hospital-Acquired Infections Assays in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hospital-Acquired Infections Assays in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hospital-Acquired Infections Assays Industry Trends Table 2. Hospital-Acquired Infections Assays Industry Drivers Table 3. Hospital-Acquired Infections Assays Industry Opportunities and Challenges Table 4. Hospital-Acquired Infections Assays Industry Restraints Table 5. Global Hospital-Acquired Infections Assays Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hospital-Acquired Infections Assays Revenue Share by Company (2021-2026) Table 7. Global Hospital-Acquired Infections Assays Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hospital-Acquired Infections Assays Key Company Manufacturing Base & Headquarters Table 9. Global Hospital-Acquired Infections Assays Company, Product Type & Application Table 10. Global Hospital-Acquired Infections Assays Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hospital-Acquired Infections Assays by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Tests Table 15. Significant Companies of Urinalysis Table 16. Global Hospital-Acquired Infections Assays Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Hospital-Acquired Infections Assays Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Hospital-Acquired Infections Assays Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Hospital-Acquired Infections Assays Sales Value Share by Type (2021-2026) Table 20. Global Hospital-Acquired Infections Assays Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Urinary Tract Infections Table 22. Significant Companies of Pneumonia Table 23. Significant Companies of Surgical Site Infections Table 24. Significant Companies of Bloodstream Infections Table 25. Significant Companies of Other Hospital Infections Table 26. Global Hospital-Acquired Infections Assays Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hospital-Acquired Infections Assays Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Hospital-Acquired Infections Assays Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Hospital-Acquired Infections Assays Sales Value Share by Application (2021-2026) Table 30. Global Hospital-Acquired Infections Assays Sales Value Share by Application (2027-2032) Table 31. Global Hospital-Acquired Infections Assays Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hospital-Acquired Infections Assays Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Hospital-Acquired Infections Assays Sales Value Share by Region (2021-2026) Table 34. Global Hospital-Acquired Infections Assays Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Hospital-Acquired Infections Assays Sales Value Share by Region (2027-2032) Table 36. Global Hospital-Acquired Infections Assays Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hospital-Acquired Infections Assays Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Hospital-Acquired Infections Assays Sales Value Market Share by Country (2021-2026) Table 39. Global Hospital-Acquired Infections Assays Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Hospital-Acquired Infections Assays Sales Value Market Share by Country (2027-2032) Table 41. BIOMÉRIEUX Company Information Table 42. BIOMÉRIEUX Business Overview Table 43. BIOMÉRIEUX Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. BIOMÉRIEUX Hospital-Acquired Infections Assays Product Portfolio Table 45. BIOMÉRIEUX Recent Development Table 46. Abbott Company Information Table 47. Abbott Business Overview Table 48. Abbott Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abbott Hospital-Acquired Infections Assays Product Portfolio Table 50. Abbott Recent Development Table 51. F. Hoffmann-La Roche Ltd. Company Information Table 52. F. Hoffmann-La Roche Ltd. Business Overview Table 53. F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Product Portfolio Table 55. F. Hoffmann-La Roche Ltd. Recent Development Table 56. Siemens Healthcare Private Limited Company Information Table 57. Siemens Healthcare Private Limited Business Overview Table 58. Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Product Portfolio Table 60. Siemens Healthcare Private Limited Recent Development Table 61. BD (Becton, Dickinson and Company) Company Information Table 62. BD (Becton, Dickinson and Company) Business Overview Table 63. BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Product Portfolio Table 65. BD (Becton, Dickinson and Company) Recent Development Table 66. Bioscience, Inc. Company Information Table 67. Bioscience, Inc. Business Overview Table 68. Bioscience, Inc. Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 70. Bioscience, Inc. Recent Development Table 71. QIAGEN Company Information Table 72. QIAGEN Business Overview Table 73. QIAGEN Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. QIAGEN Hospital-Acquired Infections Assays Product Portfolio Table 75. QIAGEN Recent Development Table 76. Thermo Fisher Scientific Inc. Company Information Table 77. Thermo Fisher Scientific Inc. Business Overview Table 78. Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Product Portfolio Table 80. Thermo Fisher Scientific Inc. Recent Development Table 81. Meridian Bioscience, Inc. Company Information Table 82. Meridian Bioscience, Inc. Business Overview Table 83. Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 85. Meridian Bioscience, Inc. Recent Development Table 86. Hologic, Inc. Company Information Table 87. Hologic, Inc. Business Overview Table 88. Hologic, Inc. Hospital-Acquired Infections Assays Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hologic, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 90. Hologic, Inc. Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Hospital-Acquired Infections Assays Product Image Figure 2. Global Hospital-Acquired Infections Assays Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital-Acquired Infections Assays Market Size (2021-2032) & (US$ Million) Figure 4. Global Hospital-Acquired Infections Assays Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Tests Image Figure 8. Urinalysis Image Figure 9. Global Hospital-Acquired Infections Assays Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Hospital-Acquired Infections Assays Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Hospital-Acquired Infections Assays Sales Value Share by Type (2021-2032) Figure 12. Urinary Tract Infections Image Figure 13. Pneumonia Image Figure 14. Surgical Site Infections Image Figure 15. Bloodstream Infections Image Figure 16. Other Hospital Infections Image Figure 17. Global Hospital-Acquired Infections Assays Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hospital-Acquired Infections Assays Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hospital-Acquired Infections Assays Sales Value Share by Application (2021-2032) Figure 20. Global Hospital-Acquired Infections Assays Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Hospital-Acquired Infections Assays Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Hospital-Acquired Infections Assays Sales Value (2021-2032) & (US$ Million) Figure 23. North America Hospital-Acquired Infections Assays Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Hospital-Acquired Infections Assays Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Hospital-Acquired Infections Assays Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Hospital-Acquired Infections Assays Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Hospital-Acquired Infections Assays Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Hospital-Acquired Infections Assays Sales Value (2021-2032) & (US$ Million) Figure 29. South America Hospital-Acquired Infections Assays Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Hospital-Acquired Infections Assays Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Hospital-Acquired Infections Assays Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Tests
  • Urinalysis
Applications
  • Urinary Tract Infections
  • Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections
Companies covered
  • BIOMÉRIEUX
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • BD (Becton, Dickinson and Company)
  • Bioscience, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hospital-Acquired Infections Assays Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hospital-Acquired Infections Assays Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hospital-Acquired Infections Assays Market Dynamics
  1. 2.1 Hospital-Acquired Infections Assays Industry Trends
  2. 2.2 Hospital-Acquired Infections Assays Industry Drivers
  3. 2.3 Hospital-Acquired Infections Assays Industry Opportunities and Challenges
  4. 2.4 Hospital-Acquired Infections Assays Industry Restraints
3 Hospital-Acquired Infections Assays Market by Company
  1. 3.1 Global Hospital-Acquired Infections Assays Company Revenue Ranking in 2025
  2. 3.2 Global Hospital-Acquired Infections Assays Revenue by Company (2021-2026)
  3. 3.3 Global Hospital-Acquired Infections Assays Company Ranking (2024-2026)
  4. 3.4 Global Hospital-Acquired Infections Assays Company Manufacturing Base and Headquarters
  5. 3.5 Global Hospital-Acquired Infections Assays Company Product Type and Application
  6. 3.6 Global Hospital-Acquired Infections Assays Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hospital-Acquired Infections Assays Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hospital-Acquired Infections Assays Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hospital-Acquired Infections Assays Market by Type
  1. 4.1 Hospital-Acquired Infections Assays Type Introduction
  2. 4.1.1 Blood Tests
  3. 4.1.2 Urinalysis
  4. 4.2 Global Hospital-Acquired Infections Assays Sales Value by Type
  5. 4.2.1 Global Hospital-Acquired Infections Assays Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hospital-Acquired Infections Assays Sales Value by Type (2021-2032)
  7. 4.2.3 Global Hospital-Acquired Infections Assays Sales Value Share by Type (2021-2032)
5 Hospital-Acquired Infections Assays Market by Application
  1. 5.1 Hospital-Acquired Infections Assays Application Introduction
  2. 5.1.1 Urinary Tract Infections
  3. 5.1.2 Pneumonia
  4. 5.1.3 Surgical Site Infections
  5. 5.1.4 Bloodstream Infections
  6. 5.1.5 Other Hospital Infections
  7. 5.2 Global Hospital-Acquired Infections Assays Sales Value by Application
  8. 5.2.1 Global Hospital-Acquired Infections Assays Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Hospital-Acquired Infections Assays Sales Value by Application (2021-2032)
  10. 5.2.3 Global Hospital-Acquired Infections Assays Sales Value Share by Application (2021-2032)
6 Hospital-Acquired Infections Assays Regional Value Analysis
  1. 6.1 Global Hospital-Acquired Infections Assays Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hospital-Acquired Infections Assays Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hospital-Acquired Infections Assays Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hospital-Acquired Infections Assays Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hospital-Acquired Infections Assays Sales Value (2021-2032)
  7. 6.3.2 North America Hospital-Acquired Infections Assays Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hospital-Acquired Infections Assays Sales Value (2021-2032)
  10. 6.4.2 Europe Hospital-Acquired Infections Assays Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hospital-Acquired Infections Assays Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hospital-Acquired Infections Assays Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hospital-Acquired Infections Assays Sales Value (2021-2032)
  16. 6.6.2 South America Hospital-Acquired Infections Assays Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hospital-Acquired Infections Assays Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hospital-Acquired Infections Assays Sales Value Share by Country, 2025 VS 2032
7 Hospital-Acquired Infections Assays Country-level Value Analysis
  1. 7.1 Global Hospital-Acquired Infections Assays Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hospital-Acquired Infections Assays Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hospital-Acquired Infections Assays Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hospital-Acquired Infections Assays Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hospital-Acquired Infections Assays Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hospital-Acquired Infections Assays Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hospital-Acquired Infections Assays Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BIOMÉRIEUX
  2. 8.1.1 BIOMÉRIEUX Company Information
  3. 8.1.2 BIOMÉRIEUX Business Overview
  4. 8.1.3 BIOMÉRIEUX Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BIOMÉRIEUX Hospital-Acquired Infections Assays Product Portfolio
  6. 8.1.5 BIOMÉRIEUX Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Hospital-Acquired Infections Assays Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Siemens Healthcare Private Limited
  20. 8.4.1 Siemens Healthcare Private Limited Company Information
  21. 8.4.2 Siemens Healthcare Private Limited Business Overview
  22. 8.4.3 Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Product Portfolio
  24. 8.4.5 Siemens Healthcare Private Limited Recent Developments
  25. 8.5 BD (Becton, Dickinson and Company)
  26. 8.5.1 BD (Becton, Dickinson and Company) Company Information
  27. 8.5.2 BD (Becton, Dickinson and Company) Business Overview
  28. 8.5.3 BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Product Portfolio
  30. 8.5.5 BD (Becton, Dickinson and Company) Recent Developments
  31. 8.6 Bioscience, Inc.
  32. 8.6.1 Bioscience, Inc. Company Information
  33. 8.6.2 Bioscience, Inc. Business Overview
  34. 8.6.3 Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
  36. 8.6.5 Bioscience, Inc. Recent Developments
  37. 8.7 QIAGEN
  38. 8.7.1 QIAGEN Company Information
  39. 8.7.2 QIAGEN Business Overview
  40. 8.7.3 QIAGEN Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  41. 8.7.4 QIAGEN Hospital-Acquired Infections Assays Product Portfolio
  42. 8.7.5 QIAGEN Recent Developments
  43. 8.8 Thermo Fisher Scientific Inc.
  44. 8.8.1 Thermo Fisher Scientific Inc. Company Information
  45. 8.8.2 Thermo Fisher Scientific Inc. Business Overview
  46. 8.8.3 Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Product Portfolio
  48. 8.8.5 Thermo Fisher Scientific Inc. Recent Developments
  49. 8.9 Meridian Bioscience, Inc.
  50. 8.9.1 Meridian Bioscience, Inc. Company Information
  51. 8.9.2 Meridian Bioscience, Inc. Business Overview
  52. 8.9.3 Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
  54. 8.9.5 Meridian Bioscience, Inc. Recent Developments
  55. 8.10 Hologic, Inc.
  56. 8.10.1 Hologic, Inc. Company Information
  57. 8.10.2 Hologic, Inc. Business Overview
  58. 8.10.3 Hologic, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hologic, Inc. Hospital-Acquired Infections Assays Product Portfolio
  60. 8.10.5 Hologic, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst